Inflammation and cancer: Role of nuclear factor‐kappaB activation

It has been thought that there is a strong relationship between inflammation and carcinogenesis so that the development of cancer occurs with chronic inflammation in many organs. An in‐depth understanding of the mechanism by which inflammation can lead to carcinogenesis may enable the development of drugs targeted at important molecules, providing a powerful tool for preventing cancer development. In this review, we focused on a signal transduction system, the nuclear factor‐kappaB (NF‐κB) pathway, which is thought to play a role in the process leading from inflammation to carcinogenesis, and may thus serve as a candidate for targeted intervention. (Cancer Sci 2008; 99: 836–842)

[1]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[2]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[3]  M. Karin,et al.  The two NF-κB activation pathways and their role in innate and adaptive immunity , 2004 .

[4]  M. Karin,et al.  Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2009, Nature.

[5]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[6]  Y. Shiratori,et al.  Virulence Factors of Helicobacter pylori Responsible for Gastric Diseases in Mongolian Gerbil , 2000, The Journal of experimental medicine.

[7]  P. Schofield,et al.  Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. , 1995, Anticancer research.

[8]  T. Kawabe,et al.  MyD88 and TNF Receptor-Associated Factor 6 Are Critical Signal Transducers in Helicobacter pylori-Infected Human Epithelial Cells1 , 2006, The Journal of Immunology.

[9]  D. Seldin,et al.  RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. , 2005, Molecular and cellular biology.

[10]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[11]  M. Karin,et al.  The two NF-kappaB activation pathways and their role in innate and adaptive immunity. , 2004, Trends in immunology.

[12]  A. Hoffmann,et al.  Circuitry of nuclear factor kappaB signaling. , 2006, Immunological reviews.

[13]  A. Ma,et al.  Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. , 2000, Science.

[14]  A. Porter,et al.  NF-κB Activation Mediates Doxorubicin-induced Cell Death in N-type Neuroblastoma Cells* , 2001, The Journal of Biological Chemistry.

[15]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[16]  M. Borodovsky,et al.  cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[18]  David A. Cheresh,et al.  Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2007, Nature.

[19]  T. Shono,et al.  Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis , 1997, Molecular and cellular biology.

[20]  R. Kiesslich,et al.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.

[21]  Sm,et al.  and Gastric Cancer , 2009 .

[22]  S. Weitzman,et al.  Chronic inflammation and cancer. , 2002, Oncology.

[23]  T. Deerinck,et al.  The IKKβ Subunit of IκB Kinase (IKK) is Essential for Nuclear Factor κB Activation and Prevention of Apoptosis , 1999, The Journal of experimental medicine.

[24]  Michael Karin,et al.  IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy , 2005 .

[25]  B. Huhse,et al.  CD40 regulates the processing of NF‐κB2 p100 to p52 , 2002 .

[26]  D. Green,et al.  The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. , 2002, Immunity.

[27]  M. Omata,et al.  Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. , 2007, Biochemical and biophysical research communications.

[28]  R. P. Blankfield,et al.  Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.

[29]  David Baltimore,et al.  Two Pathways to NF-κB , 2002 .

[30]  M. Toi,et al.  Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.

[31]  M. Karin,et al.  IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. , 2003, Immunity.

[32]  M. Karin,et al.  Inhibition of JNK activation through NF-kappaB target genes. , 2001, Nature.

[33]  Y. Shiratori,et al.  Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. , 2002 .

[34]  L. Ulloa,et al.  High-mobility group box 1 (HMGB1) protein: friend and foe. , 2006, Cytokine & growth factor reviews.

[35]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[36]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[37]  G. Courtois,et al.  The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination , 2003, Nature.

[38]  M. Blaser,et al.  Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. , 1991, The New England journal of medicine.

[39]  K. Bodger,et al.  Helicobacter pylori and gastric inflammation. , 1998, British medical bulletin.

[40]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[41]  S. Johansson,et al.  Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A , 2005, Melanoma research.

[42]  Y. Shiratori,et al.  Structure of cag pathogenicity island in Japanese Helicobacter pyloriisolates , 1999, Gut.

[43]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[44]  J. Pober,et al.  Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. , 2000, Science.

[45]  Michael Karin,et al.  NF-kappaB at the crossroads of life and death. , 2002, Nature immunology.

[46]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[47]  Michael Karin,et al.  IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. , 2005, The Journal of clinical investigation.

[48]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[49]  Z. Ronai,et al.  p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-κB activity and Fas expression , 2000, Oncogene.

[50]  J. Kirkwood,et al.  Interferon therapy. , 1982, World Health Organization technical report series.

[51]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[52]  Y. Yamaji,et al.  H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. , 2000, Gastroenterology.

[53]  D. Green,et al.  Regional analysis of p53 mutations in rheumatoid arthritis synovium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Hong-shan Wang,et al.  BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. , 2002, Nature immunology.

[55]  H. Bartsch,et al.  Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. , 2004, Cancer detection and prevention.

[56]  A. Itai,et al.  Activation of IkappaB kinase and NF-kappaB is essential for Helicobacter pylori-induced chronic gastritis in Mongolian gerbils. , 2008, Infection and immunity.

[57]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[58]  A. Itai,et al.  Activation of IκB Kinase β and NF-κB Is Essential for Helicobacter pylori-Induced Chronic Gastritis in Mongolian Gerbils , 2007, Infection and Immunity.

[59]  M. Karin,et al.  Inhibition of JNK activation through NF-κB target genes , 2001, Nature.

[60]  S. Ghosh,et al.  Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex , 2000 .

[61]  David Baltimore,et al.  Two pathways to NF-kappaB. , 2002, Molecular cell.

[62]  A. Porter,et al.  NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. , 2001, The Journal of biological chemistry.

[63]  P. Szlosarek,et al.  Tumour necrosis factor α: a potential target for the therapy of solid tumours , 2003 .

[64]  P. Szlosarek,et al.  Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. , 2003, The Lancet. Oncology.

[65]  R. Strieter,et al.  Role of C‐X‐C chemokines as regulators of angiogenesis in lung cancer , 1995, Journal of leukocyte biology.

[66]  M. Omata,et al.  Cutting Edge: The IκB Kinase (IKK) Inhibitor, NEMO-Binding Domain Peptide, Blocks Inflammatory Injury in Murine Colitis1 , 2007, The Journal of Immunology.

[67]  Manish Gala,et al.  Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells , 2005, Nature Medicine.

[68]  T. Wang,et al.  Inflammation, atrophy, and gastric cancer. , 2007, The Journal of clinical investigation.

[69]  M. Karin,et al.  IKKβ Is Required for Prevention of Apoptosis Mediated by Cell-Bound but Not by Circulating TNFα , 2003 .

[70]  John Bertin,et al.  Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island , 2004, Nature Immunology.

[71]  D. Green,et al.  The Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression via Two NF-κB Pathways , 2002 .

[72]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[73]  D. Seldin,et al.  RelB/p52 NF-κB Complexes Rescue an Early Delay in Mammary Gland Development in Transgenic Mice with Targeted Superrepressor IκB-α Expression and Promote Carcinogenesis of the Mammary Gland , 2005, Molecular and Cellular Biology.

[74]  Chris Albanese,et al.  NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1 , 1999, Molecular and Cellular Biology.

[75]  Hong-shan Wang,et al.  BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells , 2002, Nature Immunology.

[76]  Masakazu Toi,et al.  Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.

[77]  M. Karin,et al.  Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[78]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[79]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[80]  Y. Yamaji,et al.  H. pylori activates NF-κB through a signaling pathway involving IκB kinases, NF-κB—inducing kinase, TRAF2, and TRAF6 in gastric cancer cells☆ , 2000 .